Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancer von Peeters, M., Price, T.J., Cervantes, A., Sobrero, A.F., Ducreux, M., Hotko, Y., André, T., Chan, E., Lordick, F., Punt, C.J.A., Strickland, A.H., Wilson, G., Ciuleanu, T.E., Roman, L., Van Cutsem, E., Tian, Y., Sidhu, R.

Volltext

Fluorouracil in colorectal cancer--a tale of two drugs: implications for biochemical modulation von SOBRERO, A. F, ASCHELE, C, BERTINO, J. R

Volltext

Taxane-induced nail changes: incidence, clinical presentation and outcome von Minisini, A. M., Tosti, A., Sobrero, A. F., Mansutti, M., Piraccini, B. M., Sacco, C., Puglisi, F.

Volltext

Two doses of NGR-hTNF in combination with capecitabine plus oxaliplatin in colorectal cancer patients failing standard therapies von Mammoliti, S., Andretta, V., Bennicelli, E., Caprioni, F., Comandini, D., Fornarini, G., Guglielmi, A., Pessino, A., Sciallero, S., Sobrero, A.F., Mazzola, G., Lambiase, A., Bordignon, C.

Volltext

Schedule-dependent synergism between raltitrexed and irinotecan in human colon cancer cells in vitro von ASCHELE, C, BALDO, C, SOBRERO, A. F, DEBERNARDIS, D, BORNMANN, W. G, BERTINO, J. R

Volltext

Duration of Adjuvant Chemotherapy for Stage III Colon Cancer von Grothey, Axel, Sobrero, Alberto F, Shields, Anthony F, Yoshino, Takayuki, Paul, James, Taieb, Julien, Souglakos, John, Shi, Qian, Kerr, Rachel, Labianca, Roberto, Meyerhardt, Jeffrey A, Vernerey, Dewi, Yamanaka, Takeharu, Boukovinas, Ioannis, Meyers, Jeffrey P, Renfro, Lindsay A, Niedzwiecki, Donna, Watanabe, Toshiaki, Torri, Valter, Saunders, Mark, Sargent, Daniel J, Andre, Thierry, Iveson, Timothy

Volltext

Synergism and Lack of Cross-resistance Between Short-term and Continuous Exposure to Fluorouracil in Human Colon Adenocarcinoma Cells von Sobrero, Alberto F., Aschele, Carlo, Guglielmi, Alessandra P., Mori, Ave M., Melioli, Giovanni G., Rosso, Riccardo, Bertino, Joseph R.

Volltext

Does biomodulation of 5-fluorouracil improve results? von SOBRERO, A. F, HERRMANN, R, RISCHIN, D, ZALCBERG, J

Volltext

Schedule-selective biochemical modulation of 5-fluorouracil: a phase II study in advanced colorectal cancer von SOBRERO, A. F, ASCHELE, C, BRUZZI, P, BERTINO, J. R, GUGLIELMI, A. P, MORI, A. M, TIXI, L. M, BOLLI, E. A, ROSSO, R, MAMMOLITI, S, ROLLANDI, G. A, BERTOGLIO, S

Volltext

Impact on quality of life of adding cetuximab to irinotecan in patients who have failed prior oxaliplatin-based therapy: The EPIC trial von Eng, C., Maurel, J., Scheithauer, W., Wong, L., Lutz, M., Middleton, G., Stoller, R., Zubel, A., Lu, H., Sobrero, A. F.

Volltext

Defective facilitated diffusion of nucleosides, a primary mechanism of resistance to 5-fluoro-2'-deoxyuridine in the HCT-8 human carcinoma line von SOBRERO, A. F, MOIR, R. D, BERTINO, J. R, HANDSCHUMACHER, R. E

Volltext

Mechanism of action of 5,8-dideazaisofolic acid and other quinazoline antifols in human colon carcinoma cells von MCGUIRE, J. J, SOBRERO, A. F, HYNES, J. B, BERTINO, J. R

Volltext

Results of a Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial (CORRECT) of Regorafenib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients... von Yoshino, T., Van Cutsem, E., Sobrero, A. F, Siena, S., Falcone, A., Ychou, M., Lenz, H.-J., Cihon, F., Wagner, A., Grothey, A.

Volltext

Uptake and metabolism of 5,8-dideazaisofolic acid in human colon carcinoma cells von Sobrero, Alberto F., McGuire, John J., Bertino, Joseph R.

Volltext

Axitinib or bevacizumab (bev) plus FOLFOX or FOLFIRI as second-line therapy in patients (pts) with metastatic colorectal cancer (mCRC) von Bendell, J. C., Tournigand, C., Bednarczyk, M., Swieboda-Sadlej, A., Chung, I., Barone, C., Tarazi, J. C., Rosbrook, B., Ricart, A. D., Sobrero, A. F.

Volltext

Randomized, open-label, phase III study of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (m... von Price, T. J., Sobrero, A. F., Wilson, G., Van Cutsem, E., Aleknaviciene, B., Zaniboni, A., Hartmann, J. T., Tian, Y., Gansert, J. L., Peeters, M.

Volltext

Sorafenib plus chemotherapy versus chemotherapy alone in advanced pancreatic cancer: A randomized phase II trial von Cascinu, S., Berardi, R., Sobrero, A. F., Labianca, R., Bidoli, P., Siena, S., Ferraris, D., Barni, S., Cengarle, R., Monteforte, M.

Volltext

Two doses of NGR-hTNF combined with capecitabine/oxaliplatin (XELOX) in colorectal cancer (CRC) patients failing standard regimens: A phase II study von Di Benedetto, M., Bennicelli, E., Andretta, V., Pessino, A., Guglielmi, A., Sciallero, M. S., Sobrero, A. F., Fornarini, G., Lambiase, A., Bordignon, C.

Volltext

Phase II study of NGR-hTNF, a selective vascular targeting agent (VTA), administered as single agent in patients (pts) with colorectal cancer (CRC) refractory to standard regimens von Rimassa, L., Sobrero, A. F., Santoro, A., Andretta, V., Gregorc, V., Sclafani, F., Caprioni, F., Caligaris-Cappio, F., Lambiase, A., Bordignon, C.

Volltext

Phase II trial of imatinib, bevacizumab and cetuximab plus modified FOLFOX-6 in advanced untreated colorectal cancer von Sobrero, A. F., Bennicelli, E., Pessino, A., Guglielmi, A., Mammoliti, S., Caprioni, F., Fornarini, G., Comandini, D., Sciallero, S., Ansaldi, F.

Volltext